tbuckley/cabot-search huggingface dataset:
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results
Authors: David M. Fleischer, Wayne G. Shreffler, Dianne E. Campbell, Todd D. Green, Sara Anvari, Amal Assa’ad, Philippe Bégin, Kirsten Beyer, J. Andrew Bird, Terri Brown-Whitehorn, Aideen Byrne, Edmond S. Chan, Amarjit Cheema, Sharon Chinthrajah, Hey Jin Chong, Carla M. Davis, Lara S. Ford, Rémi Gagnon, Matthew Greenhawt, Jonathan O’B. Hourihane, Stacie M. Jones, Edwin H. Kim, Lars Lange, Bruce J. Lanser, Stephanie Leonard, Vera Mahler, Andreas Maronna, Anna Nowak-Wegrzyn, Roxanne C. Oriel, Michael O’Sullivan, Daniel Petroni, Jacqueline A. Pongracic, Susan L. Prescott, Lynda C. Schneider, Peter Smith, Doris Staab, Gordon Sussman, Robert Wood, William H. Yang, Romain Lambert, Aurélie Peillon, Timothée Bois, Hugh A. Sampson
Journal: Journal of Allergy and Clinical Immunology (2020)

The PEPITES (Peanut EPIT Efficacy and Safety) trial, a 12-month randomized controlled study of children with peanut allergy and 4 to 11 years old, previously reported the safety and efficacy of epicutaneous immunotherapy (EPIT) for peanut allergy (250 μg, daily epicutaneous peanut protein; DBV712 250 μg).We sought to assess interim safety and efficacy of an additional 2 years of EPIT from the ongoing (5-year treatment) PEOPLE (PEPITES Open-Label Extension) study.Subjects who completed PEPITES were offered enrollment in PEOPLE. Following an additional 2 years of daily DBV712 250 μg, subjects who had received DBV712 250 μg in PEPITES underwent month-36 double-blind, placebo-controlled food challenge with an optional month-38 sustained unresponsiveness assessment.Of 213 eligible subjects who had received DBV712 250 μg in PEPITES, 198 (93%) entered PEOPLE, of whom 141 (71%) had assessable double-blind, placebo-controlled food challenge at month 36. At month 36, 51.8% of subjects (73 of 141) reached an eliciting dose of ≥1000 mg, compared with 40.4% (57 of 141) at month 12; 75.9% (107 of 141) demonstrated increased eliciting dose compared with baseline; and 13.5% (19 of 141) tolerated the full double-blind, placebo-controlled food challenge of 5444 mg. Median cumulative reactive dose increased from 144 to 944 mg. Eighteen subjects underwent an optional sustained unresponsiveness assessment; 14 of those (77.8%) maintained an eliciting dose of ≥1000 mg at month 38. Local patch-site skin reactions were common but decreased over time. There was no treatment-related epinephrine use in years 2 or 3. Compliance was high (96.9%), and withdrawals due to treatment-related adverse events were low (1%).These results demonstrate that daily EPIT treatment for peanut allergy beyond 1 year leads to continued response from a well-tolerated, simple-to-use regimen.
P-72 Biomarkers of survival and therapeutic response to hepatic radioembolization with yttrium-90 spheres in hepatocellular carcinoma
Authors: A. Rodríguez-Fernández, E. Triviño-Ibáñez, P. Pardo-Moreno, G. Ruiz-Villarverde, C. Ramos-Font
Journal: Annals of Oncology (2020)
P-9 A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
Authors: S. Belhadef, A. Arab, M. Belmadi, M. Beninal, N. Bacha, R. Abdallah, K. Mechta, A. Dahmane, H. Mahfouf, M. Oukkal, K. Bouzid, S. Faraqun, K. Bentabak, S. Ait Younes
Journal: Annals of Oncology (2020)
The role of the Rb/E2F1 tumor suppressor pathway in nucleotide excision repair
Authors: Patrick S. Lin, Julien Sage, James M. Ford
Journal: Cancer Research (2006)

818   The retinoblastoma (Rb)/E2F1 tumor suppressor pathway plays a major role in the regulation of mammalian cell cycle progression and cell proliferation. Deregulation of this pathway is frequently regarded as a fundamental characteristic of tumorigenesis in human cancer. The Rb protein, along with closely related proteins p107 and p130, exerts its anti-proliferative effects by binding to the E2F family of transcription factors known to regulate essential genes throughout the cell cycle. To determine if deregulation of the Rb/E2F1 pathway can affect nucleotide excision repair (NER), we assayed the ability of wildtype (WT) and various Rb-deficient mouse embryonic fibroblasts (MEFs) to repair DNA lesions following UV-C irradiation. Rb-/-;p107-/-;p130-/- triple knockout (TKO) MEFs repaired both cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs) at higher efficiency than did WT MEFs, while Rb-/- single mutant MEFs and p107-/-;p130-/- double mutant MEFs exhibited intermediate repair phenotypes. Given that DNA lesion recognition is the rate-limiting step in NER, we examined the expression of the Damaged DNA Binding 2 (DDB2) gene by real time RT-PCR and showed a 2.5-fold and 3.8-fold increase in DDB2 transcript levels in Rb-/- and Rb TKO MEFs, respectively. Based on recent evidence indicating that E2F1 is a mediator of DNA damage response and a putative regulator of DNA repair genes, we assayed the ability of E2F1-deficient cells to repair UV-induced DNA lesions. We demonstrated that E2F1-/- MEFs are impaired for the removal CPDs and 6-4PPs by 25-30%. Furthermore, WT MEFs induced a higher expression of DDB2 transcript level than did E2F1-/- MEFs at 16 and 24 hours following UV-C irradiation. This data is consistent with the recent finding that the DDB2 gene contains a putative E2F binding site in its promoter. Experiments are underway to determine if overexpression of DDB2 in E2F1-/- MEFs can partially or completely restore NER. Our study here suggests a regulatory role of the Rb/E2F1 tumor suppressor pathway in DNA damage repair.
Sierra: discovery of differential transcript usage from polyA-captured single-cell RNA-seq data
Authors: Ralph Patrick, David T. Humphreys, Vaibhao Janbandhu, Alicia Oshlack, Joshua W.K. Ho, Richard P. Harvey, Kitty K. Lo
Journal: Genome biology (2020)

High-throughput single-cell RNA-seq (scRNA-seq) is a powerful tool for studying gene expression in single cells. Most current scRNA-seq bioinformatics tools focus on analysing overall expression levels, largely ignoring alternative mRNA isoform expression. We present a computational pipeline, Sierra, that readily detects differential transcript usage from data generated by commonly used polyA-captured scRNA-seq technology. We validate Sierra by comparing cardiac scRNA-seq cell types to bulk RNA-seq of matched populations, finding significant overlap in differential transcripts. Sierra detects differential transcript usage across human peripheral blood mononuclear cells and the Tabula Muris, and 3 'UTR shortening in cardiac fibroblasts. Sierra is available at https://github.com/VCCRI/Sierra .
Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?
Authors: Pedro Santos-Moreno, Diana Buitrago-Garcia, Laura Villarreal, Anggie Aza, Michael Cabrera, Wilberto Rivero, Adriana Rojas-Villarraga
Journal: Annals of the Rheumatic Diseases (2020)

Aim: The aim of the study was to assess the degree to which tissue polypeptide antigen (TPA) and tissue polypeptide-specific antigen (TPS), as well as carcinoembryonic antigen (CEA), can assist in the detection of distant metastases. Patients and Methods: We assessed 157 patients with colorectal and breast cancer divided into two groups. The first was a group of patients with cancer at stages 1, 2 and 3; the second was a group of patients with cancer at stage 4 with metastasis. Results: We found significantly higher levels of all biomarkers in the metastatic group compared to the group with cancer at stages 1-3 (p&lt;0.0001). The calculated area under the receiver operating characteristic (ROC) curve was 0.9929 for TPS, 0.9337 for TPA and 0.7234 for CEA. The cut-off was calculated for each biomarker at 95% specificity, TPS cut-off=255 IU/l (sensitivity 95%), TPA cut-off=200 IU/l (sensitivity 70%) and CEA cut-off=18 μg/l (sensitivity 37%). Conclusion: We suggest combining CEA with TPS or TPA in the detection of distant metastases or using only cytokeratins. This approach can significantly increase the quality of detection of the metastatic process.
Breastmilk Feeding Practices Are Associated with the Co-Occurrence of Bacteria in Mothers’ Milk and the Infant Gut: the CHILD Cohort Study
Authors: Kelsey Fehr, Shirin Moossavi, Hind Sbihi, Rozlyn C.T. Boutin, Lars Bode, Bianca Robertson, Chloe Yonemitsu, Catherine J. Field, Allan B. Becker, Piushkumar J. Mandhane, Malcolm R. Sears, Ehsan Khafipour, Theo J. Moraes, Padmaja Subbarao, B. Brett Finlay, Stuart E. Turvey, Meghan B. Azad
Journal: Cell Host & Microbe (2020)
Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial
Authors: Anna L. Godfrey, Peter J Campbell, Cathy MacLean, Georgina Buck, Clare L. East, Julia Cook, Julie Temple, Bridget S. Wilkins, Keith Wheatley, Jyoti Nangalia, Jacob Grinfeld, Mary Frances Frances McMullin, Cecily Forsyth, Jean-Jacques Kiladjian, Anthony R. Green, Claire N. Harrison
Journal: Blood (2017)
P-103 The role of primary tumor site as a prognostic factor after resection of colorectal liver metastases: A mono-institutional cohort study
Authors: F. Camarda, F. Ardito, M. Bensi, M. Vellone, B. Di Stefano, R. Vivolo, C. Mele, M. Ribelli, E. Panettieri, A. Frascarelli, M. Calegari, M. Basso, C. Pozzo, F. Giuliante, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2020)
Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study
Authors: Ying-Jun Chang, De-Pei Wu, Yong-Rong Lai, Qi-Fa Liu, Yu-Qian Sun, Jiong Hu, Yu Hu, Jian-Feng Zhou, Juan Li, Shun-Qing Wang, Wei Li, Xin Du, Dong-Jun Lin, Han-Yun Ren, Fang-Pin Chen, Yu-Hua Li, Xi Zhang, He Huang, Yong-Ping Song, Ming Jiang, Jian-Da Hu, Ying-Min Liang, Jing-Bo Wang, Yang Xiao, Xiao-Jun Huang
Journal: Journal of Clinical Oncology (2020)

The role of antithymocyte globulin (ATG) in preventing acute graft-versus-host disease (aGVHD) after HLA-matched sibling donor transplantation (MSDT) is still controversial.We performed a prospective, multicenter, open-label, randomized controlled trial (RCT) across 23 transplantation centers in China. Patients ages 40-60 years with standard-risk hematologic malignancies with an HLA-matched sibling donor were randomly assigned to an ATG group (4.5 mg/kg thymoglobulin plus cyclosporine [CsA], methotrexate [MTX], and mycophenolate mofetil [MMF]) and a control group (CsA, MTX, and MMF). The primary end point of this study was grade 2-4 aGVHD on day 100.From November 2013 to April 2018, 263 patients were enrolled. The cumulative incidence rate of grade 2-4 aGVHD was significantly reduced in the ATG group (13.7%; 95% CI, 13.5% to 13.9%) compared with the control group (27.0%; 95% CI, 26.7% to 27.3%; P = .007). The ATG group had significantly lower incidences of 2-year overall chronic GVHD (27.9% [95% CI, 27.6% to 28.2%] v 52.5% [95% CI, 52.1% to 52.9%]; P < .001) and 2-year extensive chronic GVHD (8.5% [95% CI, 8.4% to 8.6%] v 23.2% [95% CI, 22.9% to 23.5%]; P = .029) than the control group. There were no differences between the ATG and control groups with regard to cytomegalovirus reactivation, Epstein-Barr virus reactivation, 3-year nonrelapse mortality (NRM), 3-year cumulative incidence of relapse (CIR), 3-year overall survival, or 3-year leukemia-free survival. Three-year GVHD relapse-free survival was significantly improved in the ATG group (38.7%; 95% CI, 29.9% to 47.5%) compared with the control group (24.5%; 95% CI, 16.9% to 32.1%; P = .003).Our study is the first prospective RCT in our knowledge to demonstrate that ATG can effectively decrease the incidence of aGVHD after MSDT in the CsA era without affecting the CIR or NRM.
P-384 Quality of life and the systemic pharmacokinetics of oxaliplatin in patients with unresectable peritoneal metastases from colorectal cancer treated with repetitive electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC): The CRC-PIPAC trial
Authors: R. Lurvink, K. Rovers, R. Tajzai, E. Wassenaar, F. Mols, D. Moes, G. Pluimakers, M. Wiezer, J. Burger, S. Nienhuijs, D. Boerma, M. Deenen, I. de Hingh
Journal: Annals of Oncology (2020)
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Authors: David G. Pfister, Sharon Spencer, David Adelstein, Douglas Adkins, Yoshimi Anzai, David M. Brizel, Justine Y. Bruce, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Moon Fenton, Robert L. Foote, Thomas Galloway, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James W. Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Gregory Weinstein, Matthew Witek, Frank Worden, Sue S. Yom, Weining Zhen, Jennifer L. Burns, Susan D. Darlow
Journal: Journal of the National Comprehensive Cancer Network (2020)

Treatment is complex for patients with head and neck (H&N) cancers with specific site of disease, stage, and pathologic findings guiding treatment decision-making. Treatment planning for H&N cancers involves a multidisciplinary team of experts. This article describes supportive care recommendations in the NCCN Guidelines for Head and Neck Cancers, as well as the rationale supporting a new section on imaging recommendations for patients with H&N cancers. This article also describes updates to treatment recommendations for patients with very advanced H&N cancers and salivary gland tumors, specifically systemic therapy recommendations.
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Authors: Kirill V. Lepik, Natalia B. Mikhailova, Elena V. Kondakova, Yuri R. Zalyalov, Liudmila V. Fedorova, Luibov A. Tsvetkova, Polina V. Kotselyabina, Evgeniya S. Borzenkova, Elena V. Babenko, Marina O. Popova, Elena I. Darskaya, Vadim V. Baykov, Ivan S. Moiseev, Boris V. Afanasyev
Journal: HemaSphere (2020)

This single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received nivolumab (3 mg/kg) on D1,14 and bendamustine (90 mg/m2) on D1, 2 of a 28-day cycle for up to 3 cycles. The ORR was 87% with 57% CR, 30% PR. With median follow-up of 25 months, the estimated 2-year OS was 96,7% (95% CI, 90.2%-100%), PFS was 23,3% (95% CI, 8.2%-38.4%) median PFS was 10.2 months (95% CI, 7.7-14.2 months) with median DOR 6.6 months (95% CI 3.9-11.6 months). Ten patients (33.3%) experienced grade 3 to 4 AE during therapy. Infections were most common AEs of the combined therapy. NB was a highly efficient salvage regimen in relapsed/refractory cHL with a manageable toxicity profile and modest potential for achievement of long-term remission. Registered at www.clinicaltrials.gov (#NCT0334365).
P-17 Peri-operative FLOT: West of Scotland regional experience
Authors: K. Welsh, H. Marashi, D. Grose, D. McIntosh, J. Evans, A. Martin, J. Graham, G. Smith, M. Forshaw, G. Fullarton, C. Craig, A. Macdonald, C. MacKay, C. Wilson
Journal: Annals of Oncology (2020)
Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
Authors: Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee
Journal: Clinical and Molecular Hepatology (2020)

Background/Aims: Stereotactic body radiation therapy (SBRT) is used as an alternative ablative treatment in patients with hepatocellular carcinoma (HCC) not suitable for curative treatments. The purpose of this prospective study was to evaluate the long-term efficacy of SBRT for small (≤5 cm) HCCs.Methods: A phase II, single-arm clinical trial on SBRT for small HCCs was conducted at an academic tertiary care center. The planned SBRT dose was 45 Gy with a fraction size of 15-Gy over 3 consecutive days. The primary endpoint was 2-year local control rate. Radiologic responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and the modified RECIST criteria.Results: Between 2013 and 2016, 50 patients (53 lesions) were enrolled, with a median follow-up period of 47.8 months (range, 2.9–70.6). Patients’ age ranged from 41 to 74 years, and 80% were male. Median tumor size was 1.3 cm (range, 0.7–3.1). The 2- and 5-year local control rates were 100% and 97.1%, respectively. The 5-year overall survival rate was 77.6%. Six months after SBRT, radiologic responses were evident in 44 lesions (83%) according to the RECIST criteria and 49 (92.4%) according to the modified RECIST criteria. None of the patients showed grade ≥3 adverse events.Conclusions: SBRT showed excellent results as an ablative treatment for patients with small HCCs while showing minimal toxicities. SBRT can be a good alternative for both curative and salvage intents in patients with HCCs that are unsuitable for curative treatments.
Monocyte-Derived Leukemia-Associated Macrophages Facilitate Extramedullary Distribution of T-cell Acute Lymphoblastic Leukemia Cells
Authors: Feifei Yang, Wenli Feng, Hao Wang, Lina Wang, Xiaoli Liu, Rong Wang, Chong Chen, Xiao Yang, Dongyue Zhang, Qian Ren, Guoguang Zheng
Journal: Cancer Research (2020)

Macrophages play important roles in both physiologic and pathologic processes and arise from successive waves of embryonic and adult hematopoiesis. Monocyte-derived macrophages (MOMF) exert distinct functions under pathologic conditions, and leukemia-associated macrophages (LAM) show considerable diversities in activation and functional phenotype. However, their origin and pathologic roles have not been well elucidated. Here we used wild-type and CCR2-/- mice to study the pathologic roles of monocyte-derived LAM in extramedullary tissues in models of Notch1-induced T-cell acute lymphoblastic leukemia (T-ALL). MOMF existed in the resting liver and spleen. In the spleen, Ly6C+ monocytes gave rise to the Ly6C+ macrophage subset. Furthermore, an increase of monocyte-derived LAM, including the Ly6C+ subset, was detected in the extramedullary tissues in leukemic mice. More monocyte-derived LAM, including Ly6C+ LAM, was detected in the spleens of leukemic mice transplanted with exogeneous mononuclear cells. Moreover, Ly6C+ LAM exhibited increased M1-related characteristics and contributed to sterile inflammation. In CCR2-/- leukemic mice, reduced Ly6C+ LAM, relieved sterile inflammation, and reduced distribution of leukemia cells were detected in extramedullary tissues. In addition, monocyte-derived Ly6C+ LAM expressed high levels of CCL8 and CCL9/10. Blocking CCR1 and CCR2 relieved hepatosplenomegaly and inhibited the extramedullary distribution of leukemia cells in T-ALL mice. Collectively, our findings reveal the multifaceted pathologic roles of monocyte-derived LAM in T-ALL progression. SIGNIFICANCE: This study links monocyte-derived leukemia-associated macrophages with noninfectious inflammation and extramedullary distribution of leukemia cells during leukemia progression, providing new insight into macrophage-based immunotherapy in leukemia.
O-1 PanCO: Updated results of an open-label, single-arm pilot study of OncoSil P-32 microparticles in unresectable locally advanced pancreatic adenocarcinoma (LAPC) with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy
Authors: P. Ross, A. Hendlisz, T. Ajithkumar, C. Iwuji, M. Harris, D. Croagh, M. Aghmesheh, A. Nagrial, N. Nguyen, M. Nikfarjam, N. Wilson, D. Kenny, D. Turner, H. Wasan
Journal: Annals of Oncology (2020)
SO-37 Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stability and microsatellite instability-high, locally advanced rectal cancer (EPOC 1504)
Authors: S. Yuki, H. Bando, Y. Tsukada, K. Inamori, Y. Komatsu, S. Homma, M. Uemura, T. Kato, D. Kotani, S. Fukuoka, N. Nakamura, M. Fukui, M. Wakabayashi, M. Kojima, A. Sato, Y. Togashi, H. Nishikawa, M. Ito, T. Yoshino
Journal: Annals of Oncology (2020)
Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors
Authors: Makiko Hayashi, Ayumi Kuga, Mikiko Suzuki, Harit Panda, Hiroshi Kitamura, Hozumi Motohashi, Masayuki Yamamoto
Journal: Cancer Research (2020)

The transcription factor Nrf2 activates transcription of cytoprotective genes during oxidative and electrophilic insults. Nrf2 activity is regulated by Keap1 in a stress-dependent manner in normal cells, and somatic loss-of-function mutations of Keap1 are known to induce constitutive Nrf2 activation, especially in lung adenocarcinomas, conferring survival and proliferative benefits to tumors. Therefore, several therapeutic strategies that aim to inhibit Nrf2 in tumors have been developed for the treatment of Nrf2-activated cancers. Here we addressed whether targeting Nrf2 activation in the microenvironment can suppress the progression of Nrf2-activated tumors. We combined two types of Keap1-flox mice expressing variable levels of Keap1 with a Kras-driven adenocarcinoma model to generate Keap1-deficient lung tumors surrounded by normal or Keap1-knockdown host cells. In this model system, activation of Nrf2 in the microenvironment prolonged the survival of Nrf2-activated tumor-bearing mice. The Nrf2-activated microenvironment suppressed tumor burden; in particular, preinvasive lesion formation was significantly suppressed. Notably, loss of Nrf2 in bone marrow-derived cells in Nrf2-activated host cells appeared to counteract the suppression of Nrf2-activated cancer progression. Thus, these results demonstrate that microenvironmental Nrf2 activation suppresses the progression of malignant Nrf2-activated tumors and that Nrf2 activation in immune cells at least partially contributes to these suppressive effects. SIGNIFICANCE: This study clarifies the importance of Nrf2 activation in the tumor microenvironment and in the host for the suppression of malignant Nrf2-activated cancers and proposes new cancer therapies utilizing inducers of Nrf2.
Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis
Authors: Marta Vuerich, Rasika Harshe, Luiza Abrahão Frank, Samiran Mukherjee, Barbora Gromova, Eva Csizmadia, Imad A.M. Nasser, Yun Ma, Alan Bonder, Vilas Patwardhan, Simon C. Robson, Maria Serena Longhi
Journal: Journal of Hepatology (2020)
SO-32 Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC
Authors: G. Argiles, J. Bendell, T. Kim, M. Wongchenko, K. DuPree, S. Mahrus, X. Qu, Y. Shi, A. Uyei, L. Roberts, Y. Yan, F. Ciardiello
Journal: Annals of Oncology (2020)
P-212 Factors affecting median PFS in patients with advanced, non-resectable well differentiated pancreatic neuroendocrine tumors treated initially with octreotide LAR - real world data
Authors: A. Kolasinska-Cwikła, J. Ćwikła, T. Bednarczuk, K. Osoweicka, A. Skowrońska, J. Pałucki, K. Roszkowska-Purska, R. Samsel, A. Cichocki
Journal: Annals of Oncology (2020)